Working… Menu
Trial record 32 of 73 for:    HYDROCHLOROTHIAZIDE AND LOSARTAN

Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension (Pathway 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00994617
Recruitment Status : Unknown
Verified June 2013 by Morris Brown, University of Cambridge.
Recruitment status was:  Recruiting
First Posted : October 14, 2009
Last Update Posted : June 12, 2013
British Heart Foundation
Information provided by (Responsible Party):
Morris Brown, University of Cambridge

Brief Summary:
To test whether the current custom of initiating treatment for hypertension with a single drug is less effective in the short-term than initial combination therapy, and results in the eventual need for comparatively more antihypertensive drug therapy.

Condition or disease Intervention/treatment Phase
Hypertension, Resistant to Conventional Therapy Essential Hypertension Drug: Losartan and hydrochlorothiazide Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks Phase 4

Detailed Description:

To determine if patients randomised to more aggressive (combination therapy) treatment for the initial treatment of hypertension have better blood pressure control compared to those randomised to less aggressive (monotherapy) treatment despite subsequent add-on treatment being similar in each group. This will test the hypothesis that monotherapy patients 'never catch up' with combination therapy patients.

  1. To determine if this 'never catch-up' phenomenon of improved BP control persists for at least one year.
  2. To understand the underlying mechanism of improved BP control; specifically:

    1. To determine if it is due to haemodynamic compensation, such as increased sodium retention and volume expansion.
    2. To determine if it is due to increased peripheral resistance.
  3. To understand the predictors of BP control i.e. age, baseline renin status, sodium status and plasma volume.
  4. To validate the National Institute for Clinical Excellence / British Hypertension Society joint guideline ACD algorithm by comparing BP control in the monotherapy crossover arm of phase 1 and to correlate this with age (≤ 55 or > 55y), and baseline characteristics such as renin.
  5. To determine the safety and tolerability of a strategy of prescribing combination therapy as the initial step versus monotherapy as the initial step.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
Study Start Date : January 2010
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Combination Therapy
Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
Drug: Losartan and hydrochlorothiazide
Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg

Active Comparator: Monotherapy
Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks
Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg

Primary Outcome Measures :
  1. Change in mean home systolic BP for the group treated initially with monotherapy compared to the group treated initially with combination therapy. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. A comparison the proportion of patients who drop out of the trial at any stage after randomisation or who require further antihypertensive treatment [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Patients must meet ALL inclusion criteria

  1. Aged 18-79
  2. Male subjects or female subjects taking adequate contraception such as the oral contraceptive pill, an intra uterine device or who are surgically sterilised or postmenopausal Females
  3. BP ≥150 mmHg (systolic) OR ≥ 95 mmHg (diastolic). Patients may be included if the PI anticipates BP criteria for inclusion will be met at randomisation
  4. Either never-treated or received a maximum of one antihypertensive drug class in the previous year

Patients will be excluded for ANY ONE of the following reasons

  1. Clinic SBP > 200 mmHg or DBP > 120 mmHg, with PI discretion to override if home BP measurements are lower
  2. Secondary or accelerated phase hypertension
  3. eGFR < 45 mls/min
  4. Contra-indication or previous intolerance to any trial therapy
  5. Failure to record required home BP readings during placebo run-in.
  6. Significant co-morbidity (investigator opinion but to include alcoholism, terminal illness, documented non-attendance at clinics etc)
  7. Diabetes type 1
  8. Plasma K+ outside normal range on two successive measurements during screening
  9. Requirement for treatment with ≥2 drugs (which can be a CCB and/or {ACEi OR ARB OR direct renin inhibitor OR β-blocker}) in order to reduce blood pressure to ≤180/120 mmHg
  10. Requirement for diuretic therapy (other than for hypertension)
  11. Requirement for ACE inhibitor (or ARB) therapy (other than for hypertension)
  12. Absolute contra-indications to any of the study drugs (listed on their data-sheet)
  13. Current therapy for cancer
  14. Anticipation of change in medical status during course of trial (e.g. planned surgical intervention requiring >2 weeks convalescence , actual or planned pregnancy)
  15. Inability to give informed consent
  16. Participation in a clinical study involving an investigational drug or device within 4 weeks of screening.
  17. Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit the subject's lifespan or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental disorders).
  18. Treatment with any of the following prohibited medications:

    1. Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study participation.

      Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid is prohibited. Chronic use is defined as >3 consecutive or nonconsecutive days of treatment per week. In addition, the intermittent use of NSAIDs is strongly discouraged throughout the duration of this study. If intermittent treatment is required, NSAIDs must not be used for more than a total of 2 days. For all subjects requiring analgesic or anti-pyretic agents, the use of paracetamol is recommended during study participation.

    2. The use of short-acting oral nitrates (eg, sublingual nitroglycerin) is permitted; however, subjects should not take short-acting oral nitrates within 4 hours of screening or any subsequent study visit.
    3. The use of long-acting oral nitrates (eg, Isordil) is permitted; however, the dose must be stable for at least 2 weeks prior to screening and randomisation.
    4. The use of sympathomimetic decongestants is permitted; however, not within 1 day prior to any clinic visit/BP assessment.
    5. The use of theophylline is permitted; however, the dose must be stable for at least 4 weeks prior to screening and throughout study participation.
    6. The use of phosphodiesterase (PDE) type V inhibitors is permitted; however, subjects must refrain from taking these medications within 1 day of screening or any subsequent study visit.
    7. The use of alpha-blockers is not permitted - with the exception of afluzosin and tamsulosin for prostatic symptoms

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00994617

Layout table for location contacts
Contact: Professor Morris Brown, FMedSCI +44 (0)1223 336743

Layout table for location information
United Kingdom
Professor Morris Brown Recruiting
Cambridge, Cambridgeshire, United Kingdom, CB22QQ
Contact: Jackie Salsbury, Nursing    01223 586878   
NHS Ayrshire Recruiting
Ayrshire, United Kingdom
Principal Investigator: Dr E Spalding         
University Hospitals Birmingham NHS Foundation Trust Recruiting
Birmingham, United Kingdom
Principal Investigator: Dr U Martin         
NHS Tayside/University of Dundee Recruiting
Dundee, United Kingdom
Principal Investigator: Prof T MacDonald         
NHS Lothian/University of Edinburgh Recruiting
Edinburgh, United Kingdom
Principal Investigator: Prof D Webb         
NHS Greater Glasgow and Clyde/University of Glasgow Recruiting
Glasgow, United Kingdom
Principal Investigator: Dr S Padmanabhan         
Ixworth GP Practice Recruiting
Ixworth, United Kingdom
Principal Investigator: Dr J Cannon         
University Hospitals of Leicester NHS Trust Recruiting
Leicester, United Kingdom
Principal Investigator: Dr A Stanley         
Barts and the London School of Medicine and Dentistry Recruiting
London, United Kingdom
Contact: Prof M Caulfield         
Principal Investigator: Prof M Caulfield         
Guys and St Thomas' NHS Foundation Trust Recruiting
London, United Kingdom
Principal Investigator: Prof K Cruickshank         
Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom
Principal Investigator: Prof P Sever         
Central Manchester University Hospitals NHS Foundation Trust Recruiting
Manchester, United Kingdom
Principal Investigator: Dr H Soran         
Norfolk and Norwich University Hospital NHS Trust Recruiting
Norwich, United Kingdom
Principal Investigator: Dr S Myint-Khin         
Sponsors and Collaborators
University of Cambridge
British Heart Foundation
Layout table for investigator information
Principal Investigator: Professor MJ Brown, FMedSci University of Cambridge

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Morris Brown, Prof Morris Brown, University of Cambridge Identifier: NCT00994617     History of Changes
Other Study ID Numbers: 2008-007749-29
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: June 12, 2013
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Essential Hypertension
Vascular Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators